Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of HGP1607 and HGP1501 in Healthy Males
NCT03089112Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Mar 2017
- Primary completion
- May 2017
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bazedoxifene and vitamin d in postmenopausal osteoporosis (6 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Area Under the Curve to the Last Measurable Concentration for HGP1607 at 120 hours, Maximum Plasma Concentration for HGP1607 at 120 hours and 2 more. Started Mar 2017; status: completed.
02
Drugs
bazedoxifenevitamin d
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT03089112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03089112.